Weekly Investment Analysts’ Ratings Updates for NovoCure (NVCR)

Several brokerages have updated their recommendations and price targets on shares of NovoCure (NASDAQ: NVCR) in the last few weeks:

• 7/24/2026 – NovoCure was given a new $32.00 price target by HC Wainwright.
• 7/24/2026 – NovoCure had its price target raised by Wedbush from $18.00 to $20.00. They now have a “neutral” rating on the stock.
• 7/23/2026 – NovoCure had its price target raised by HC Wainwright from $46.00 to $52.00. They now have a “buy” rating on the stock.
• 7/14/2026 – NovoCure was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/13/2026 – NovoCure is now covered by JPMorgan Chase & Co.. They set a “neutral” rating and a $17.00 price target on the stock.
• 6/18/2026 – NovoCure had its “buy” rating reaffirmed by HC Wainwright. They now have a $46.00 price target on the stock, down from $48.00.
• 6/1/2026 – NovoCure was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Insiders Place Their Bets

In related news, Director Timothy J. Scannell sold 2,945 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $15.77, for a total value of $46,442.65. Following the completion of the transaction, the director directly owned 14,288 shares of the company’s stock, valued at $225,321.76. This trade represents a 17.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director W Anthony Vernon sold 2,945 shares of NovoCure stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $15.77, for a total value of $46,442.65. Following the transaction, the director directly owned 197,657 shares of the company’s stock, valued at approximately $3,117,050.89. This represents a 1.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 51,943 shares of company stock worth $893,171. 5.52% of the stock is owned by insiders.

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.